Gina Mauro


Four-Year Follow-Up Shows Neoadjuvant Carboplatin/Paclitaxel Combo Improves Event-Free Survival in TNBC

September 26, 2021

A 4-year follow-up of patients with treatment-naïve triple-negative breast cancer who received carboplatin plus neoadjuvant paclitaxel, followed by doxorubicin and cyclophosphamide, suggests that the regime induces superior pathological complete response and event-free survival.